Compare Modine Manufacturing Company (MOD) vs Novavax Inc (NVAX) Price & Performance

Modine Manufacturing (MOD) trades at $182.00, down 3.93% on the day, amid a bearish technical signal and recent volatility following the completion of its Performance Technologies spin-off and merger with Gentherm. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $1.53 surpassing the $1.30 expectation. Analyst sentiment remains strongly positive with a consensus price target of $331.25, though technical indicators show selling pressure with key support at $177 and resistance at $187.

The outlook is mixed; strong analyst support and recent strategic moves like the spin-off suggest long-term growth potential, but near-term risks include integration challenges, a high P/E ratio of 67.87, and a projected decline in net profit margin for 2026. Investors should weigh solid fundamentals against current technical weakness and execution risks.

Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.

The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.